Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of “Hold” from Brokerages

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have earned an average recommendation of “Hold” from the five analysts that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $4.00.

Several analysts have commented on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a research report on Thursday. The Goldman Sachs Group lowered their price target on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a report on Friday, March 14th. Finally, StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 6th.

Institutional Investors Weigh In On Seres Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Avantax Advisory Services Inc. lifted its position in shares of Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares during the period. Jane Street Group LLC raised its stake in Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock worth $49,000 after buying an additional 37,866 shares in the last quarter. Virtu Financial LLC lifted its holdings in Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after buying an additional 18,191 shares during the period. Providence Wealth Advisors LLC boosted its position in Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 22,250 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after acquiring an additional 44,461 shares in the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Stock Down 6.1 %

Seres Therapeutics stock opened at $0.73 on Friday. The stock has a market cap of $127.45 million, a P/E ratio of -3.18 and a beta of 2.19. The company’s 50 day moving average price is $0.78 and its two-hundred day moving average price is $0.83. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.